209 related articles for article (PubMed ID: 23915145)
1. Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes.
Cheng H; Qin Y; Fan H; Su P; Zhang X; Zhang H; Zhou G
Diagn Pathol; 2013 Aug; 8():129. PubMed ID: 23915145
[TBL] [Abstract][Full Text] [Related]
2. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
Al Tamimi DM; Shawarby MA; Ahmed A; Hassan AK; AlOdaini AA
BMC Cancer; 2010 May; 10():223. PubMed ID: 20492711
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.
Feeley LP; Mulligan AM; Pinnaduwage D; Bull SB; Andrulis IL
Mod Pathol; 2014 Apr; 27(4):554-61. PubMed ID: 24051696
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
5. Effects of tissue decalcification on the quantification of breast cancer biomarkers by digital image analysis.
Gertych A; Mohan S; Maclary S; Mohanty S; Wawrowsky K; Mirocha J; Balzer B; Knudsen BS
Diagn Pathol; 2014 Nov; 9():213. PubMed ID: 25421113
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
Tendl-Schulz KA; Rössler F; Wimmer P; Heber UM; Mittlböck M; Kozakowski N; Pinker K; Bartsch R; Dubsky P; Fitzal F; Filipits M; Eckel FC; Langthaler EM; Steger G; Gnant M; Singer CF; Helbich TH; Bago-Horvath Z
Virchows Arch; 2020 Oct; 477(4):545-555. PubMed ID: 32383007
[TBL] [Abstract][Full Text] [Related]
7. The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer.
Habashy HO; Rakha EA; Ellis IO; Powe DG
Breast Cancer Res Treat; 2013 Jul; 140(2):307-16. PubMed ID: 23887673
[TBL] [Abstract][Full Text] [Related]
8. Relationship between NF-κB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer.
Shapochka DO; Zaletok SP; Gnidyuk MI
Exp Oncol; 2012 Dec; 34(4):358-63. PubMed ID: 23302996
[TBL] [Abstract][Full Text] [Related]
9. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
[TBL] [Abstract][Full Text] [Related]
10. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
[TBL] [Abstract][Full Text] [Related]
11. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
[TBL] [Abstract][Full Text] [Related]
12. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss.
Braun L; Mietzsch F; Seibold P; Schneeweiss A; Schirmacher P; Chang-Claude J; Peter Sinn H; Aulmann S
Mod Pathol; 2013 Sep; 26(9):1161-71. PubMed ID: 23558572
[TBL] [Abstract][Full Text] [Related]
14. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
15. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
16. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
17. Allelic imbalance at the HER2/TOP2A locus in breast cancer.
Huijsmans CJ; van den Brule AJ; Rigter H; Poodt J; van der Linden JC; Savelkoul PH; Hilbink M; Hermans MH
Diagn Pathol; 2015 May; 10():56. PubMed ID: 26022247
[TBL] [Abstract][Full Text] [Related]
18. Differential CARM1 expression in prostate and colorectal cancers.
Kim YR; Lee BK; Park RY; Nguyen NT; Bae JA; Kwon DD; Jung C
BMC Cancer; 2010 May; 10():197. PubMed ID: 20462455
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
20. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
